Streamlining regulatory, supply, and quality challenges
To unlock the full benefits of mergers and acquisitions (M&A), life sciences firms must first address critical challenges such as integration delays, supply disruptions, and noncompliance.
Genpact's M&A advisory services enhance supply chain integration and align product goals with regulatory needs, which can lead to growth and reduced financial impacts. Our solution delivers impact across three phases:
We assess M&A impact, determine the status of licenses and clinical trials, prioritize product needs, and manage governance.
Clients using our solution have realized regulatory, manufacturing, and quality goals and streamlined product launches.
A plan with advisory services, a sharp new tool, and an integration mindset
We combine regulatory affairs, manufacturing, and data quality into one entity. This interconnected approach helps to avoid repeat submissions, manage supply chain changes in line with regulatory timelines, and give regulators accurate data for approvals. Our robust governance process tracks and manages the merger, giving clear visibility from integration to market entry for updated products.
Impact: Enhanced insights and better resource efficiency
Our holistic approach to managing M&A in pharma offers multiple benefits. By working across functions, we enhance workload planning, resource allocation, and stakeholder visibility with real-time insights, preventing supply gaps and improving decision-making.
Our services support regulatory compliance and quality and aim to reduce the risk of penalties. We give you confidence that your company performs due diligence effectively.
- Teaser 1
- Teaser 1
- Teaser 1